6,742 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Avanza Fonder AB

Avanza Fonder AB bought a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,742 shares of the medical instruments supplier's stock, valued at approximately $1,760,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares during the period. Friedenthal Financial purchased a new stake in Insulet during the fourth quarter worth about $57,000. TD Private Client Wealth LLC grew its position in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after buying an additional 56 shares during the period. Finally, Versant Capital Management Inc increased its holdings in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after buying an additional 157 shares in the last quarter.

Insulet Trading Up 1.1 %

NASDAQ PODD traded up $2.95 during mid-day trading on Friday, hitting $275.81. The company's stock had a trading volume of 554,098 shares, compared to its average volume of 448,891. The firm has a market capitalization of $19.35 billion, a P/E ratio of 47.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.77. The stock's fifty day simple moving average is $266.30 and its two-hundred day simple moving average is $232.96.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PODD shares. Wells Fargo & Company lifted their price objective on Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Canaccord Genuity Group increased their price target on shares of Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Citigroup lifted their price objective on Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Morgan Stanley upped their target price on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Finally, TD Cowen raised their price target on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Insulet currently has an average rating of "Moderate Buy" and a consensus price target of $272.81.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company's stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.47% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.